Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / weight management (FE-Compatible plans) | Covered with prior authorization |
| Obesity / weight management (standard commercial plans, non-formulary, exception required) | Not covered |
| Obstructive sleep apnea (SURMOUNT-OSA indication, FE-Compatible plans) | Covered with prior authorization |
Aetna covers Zepbound for weight loss on FE-Compatible plan types, at BMI 30 or 27 with a weight-related condition, and dropped it from standard commercial formularies on July 1, 2025. CVS Caremark, Aetna's pharmacy benefit manager, made that cut and named Wegovy the preferred weight-loss GLP-1. On standard commercial plans Zepbound is non-formulary and needs a formulary exception with Wegovy step-through. On FE-Compatible plans prior authorization also wants six months in a structured weight-management program.
Source: Aetna Non-Medicare Prescription Drug Plan, Zepbound PA with Limit FE Compatible 6947-C P04-2025 (effective July 1, 2025). Verified June 18, 2026.
Plan type: Commercial non-Medicare.
What it costs once they say yes. With commercial insurance the manufacturer savings card takes Zepbound to as little as $25 a month. Your plan sets the copay before the card applies. What Zepbound costs with your plan.
This varies by plan. Self-funded employers set their own formularies and can elect to retain Zepbound coverage regardless of the CVS Caremark standard formulary decision. Two employees with identical Aetna cards at different companies may have different Zepbound coverage. Check your summary of benefits or call the number on your card.
Coverage by indication
| BMI threshold | BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, or cardiovascular disease) |
| Step therapy | No step therapy through other agents is specified in policy 6947-C for FE-Compatible plans. |
| Continuation | At least 5 percent loss of baseline body weight within the first 3 months of therapy |
| Authorization length | 8 months initial, 12 months continuation |
What the prior authorization needs:
- FE-Compatible plan type is required; this policy does not apply to standard commercial plan series (ACCF, ACF, ACFC, SCCF, SF, SFC, VF, VFC)
- Documented BMI within the accepted threshold
- Six months of structured weight-management program participation (behavioral modification, reduced-calorie diet, increased physical activity)
- Comorbidity documentation if BMI is 27 to 29.9
Policy 6947-C P04-2025. Source: Aetna Non-Medicare Prescription Drug Plan, Zepbound PA with Limit FE Compatible 6947-C P04-2025 (effective July 1, 2025). Official payer PA policy page (HTML). Verified June 18, 2026.
On standard commercial plan series (ACCF, ACF, ACFC, SCCF, SF, SFC, VF, VFC), Zepbound is non-formulary for weight loss since July 1, 2025. A formulary exception under policy 6981-A requires documented step-through of Wegovy (semaglutide 2.4 mg injection) before Zepbound can be approved. If Wegovy is contraindicated or not tolerated, an exception may be granted without step-through. CVS Caremark removed Zepbound from its Standard, Advanced Control, and Value formularies, affecting an estimated 200,000 patients. The Massachusetts Office of Health and Human Services documented the removal publicly.
| Effective date | 2025-07-01 |
Source: Aetna Non-Medicare Prescription Drug Plan, Zepbound Exception Policy 6981-A P04-2025 (effective July 1, 2025). Official payer PA policy page (HTML). Verified June 18, 2026.
| BMI threshold | BMI 30 or higher |
| Sleep study (AHI) | Moderate to severe OSA, AHI 15 or more obstructive respiratory events per hour confirmed by polysomnography or home sleep apnea test |
| Authorization length | 6 months initial, 12 months continuation (requires documented positive treatment response with decreased OSA symptoms) |
What the prior authorization needs:
- FE-Compatible plan type required
- Established diagnosis of moderate to severe OSA with AHI 15 or higher
- BMI 30 or higher
- Concurrent reduced-calorie diet and increased physical activity
- Documented positive treatment response required for continuation
Policy 6947-C P04-2025. Source: Aetna Non-Medicare Prescription Drug Plan, Zepbound PA with Limit FE Compatible 6947-C P04-2025 (effective July 1, 2025). Official payer PA policy page (HTML). Verified June 18, 2026.
Recent change: CVS Caremark, Aetna's pharmacy benefit manager, removed Zepbound from standard formularies effective July 1, 2025, citing a negotiated pricing deal with Novo Nordisk (Wegovy's manufacturer). Wegovy became the preferred covered weight-loss GLP-1. CVS Caremark confirmed no additional GLP-1 formulary changes for 2026. Self-funded employer plans were not bound by this decision and may retain Zepbound coverage.
Ozempic, Mounjaro and Rybelsus on Aetna plans
Ozempic, Mounjaro and Rybelsus are approved for type 2 diabetes, not weight loss.
Does Aetna cover Ozempic?
Yes, with prior approval. Aetna pays for Ozempic once your prescriber gets the plan to sign off.
Aetna covers Ozempic for type 2 diabetes, but its pharmacy benefit manager, CVS Caremark, requires prior authorization under policy 2439-C. Approval needs a documented type 2 diabetes diagnosis (for example an A1C of 6.5 percent or higher) plus one qualifying factor, such as an inadequate response to or intolerance of metformin, combination therapy with an A1C of 7.5 percent or higher, established cardiovascular disease, or chronic kidney disease. A once-weekly quantity limit of one pen per fill applies, and an approval lasts 12 months. Ozempic is not covered for weight loss; that indication belongs to Wegovy, which is the same semaglutide at a higher dose.
Verified August 27, 2026.
What Aetna requires for Ozempic
| Step therapy | Metformin inadequate response, intolerance, or contraindication is one qualifying path; documented alternatives include combination therapy with an A1C of 7.5 percent or higher, established cardiovascular disease, or chronic kidney disease. |
What the prior authorization needs:
- Documented type 2 diabetes diagnosis: A1C 6.5 percent or higher, fasting plasma glucose 126 mg/dL or higher, 2-hour OGTT plasma glucose 200 mg/dL or higher, or hyperglycemia symptoms with a random plasma glucose 200 mg/dL or higher (documentation required)
- For initial approval, patient has not already been on a stable GLP-1 or GIP/GLP-1 maintenance dose for at least 3 months
- One qualifying factor: inadequate response, intolerance, or contraindication to metformin; OR combination therapy with an A1C of 7.5 percent or higher; OR established cardiovascular disease; OR chronic kidney disease
- Quantity limit: one prefilled pen (3 mL) per 21 to 25 days for once-weekly dosing
- Prior authorization required; approval duration 12 months
Policy 2439-C. Source: Antidiabetic GLP-1, GIP-GLP-1 Agonist PA with Limit 2439-C P05-2025 v4. Official payer formulary / PA policy. Verified August 27, 2026.
Does Aetna cover Mounjaro?
Yes, with prior approval. Aetna pays for Mounjaro once your prescriber gets the plan to sign off.
Aetna covers Mounjaro for type 2 diabetes, but only with prior authorization. Its pharmacy policy approves the drug when a member has tried metformin without success, cannot take it, or needs combination therapy with an A1C of 7.5 percent or higher, and it applies quantity limits. Aetna will not cover Mounjaro for weight loss, because Mounjaro is FDA-approved for type 2 diabetes only. The weight-loss version of the same drug, tirzepatide, is sold as Zepbound and falls under a separate obesity benefit that an employer has to elect.
Verified August 27, 2026.
What Aetna requires for Mounjaro
| Step therapy |
What the prior authorization needs:
- Diagnosis of type 2 diabetes. Mounjaro is not covered for type 1 diabetes.
- One of the following: an inadequate response, intolerance, or contraindication to metformin, or a need for combination therapy with an A1C of 7.5 percent or higher.
- Quantity limit of 4 single-dose pens or vials (2 mL) per 21 days, or 12 single-dose pens or vials (6 mL) per 63 days.
- Approval lasts up to 36 months. Continuation requires a stable maintenance dose for at least 3 months and a documented A1C reduction since starting therapy.
Policy 5468-C. Source: GIP-GLP-1 Agonist Mounjaro PA with Limit Policy 5468-C: Pharmacy Clinical Policy Bulletins, Aetna Non-Medicare Prescription Drug Plan. pa-policy. Verified August 27, 2026.
Does Aetna cover Rybelsus?
Yes, with prior approval. Aetna pays for Rybelsus once your prescriber gets the plan to sign off.
Aetna covers Rybelsus for type 2 diabetes, with prior authorization required through its pharmacy benefit manager, CVS Caremark. Approval needs a documented type 2 diabetes diagnosis plus either a failed, not tolerated, or contraindicated trial of metformin, or combination therapy with an A1C of 7.5% or greater. Rybelsus is not covered for weight loss, because it has no weight-loss indication. The weight-loss semaglutide is Wegovy, which is given by injection.
Verified August 27, 2026.
What Aetna requires for Rybelsus
| Step therapy |
What the prior authorization needs:
- Documented diagnosis of type 2 diabetes
- For new starts, the patient is not already on a stable maintenance dose of a GLP-1 agonist for at least 3 months
- Inadequate response, intolerance, or contraindication to metformin, or combination therapy with an A1C of 7.5% or greater
- Quantity limit: 30 tablets per 25 days, or 90 tablets per 75 days
- Continuation of therapy requires a demonstrated A1C reduction since starting a GLP-1 agonist
- Approval duration up to 36 months
Policy 3318-C. Source: GLP-1 Agonist Rybelsus PA with Limit Policy 3318-C UDR 05-2024, Pharmacy Clinical Policy Bulletins, Aetna Non-Medicare Prescription Drug Plan. payer prior-authorization policy. Verified August 27, 2026.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does Aetna cover Zepbound?
Aetna covers Zepbound for weight loss on FE-Compatible plan types, at BMI 30 or 27 with a weight-related condition, and dropped it from standard commercial formularies on July 1, 2025. CVS Caremark, Aetna's pharmacy benefit manager, made that cut and named Wegovy the preferred weight-loss GLP-1. On standard commercial plans Zepbound is non-formulary and needs a formulary exception with Wegovy step-through. On FE-Compatible plans prior authorization also wants six months in a structured weight-management program. This reflects the published policy verified June 2026.
What does Aetna require to approve Zepbound?
For obesity / weight management (FE-Compatible plans): The BMI requirement is BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, or cardiovascular disease). No step therapy through other agents is specified in policy 6947-C for FE-Compatible plans. Authorization runs 8 months initial, 12 months continuation.
Why might Aetna deny Zepbound even if I meet the criteria?
Self-funded employers set their own formularies and can elect to retain Zepbound coverage regardless of the CVS Caremark standard formulary decision. Two employees with identical Aetna cards at different companies may have different Zepbound coverage. Check your summary of benefits or call the number on your card.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
